Etalocib is a drug under development for the treatment of various types of cancer for example non-small-cell lung carcinoma and pancreatic cancer. It acts as a leukotriene B4 receptor antagonist and a PPARγ agonist.
This page contains content from the copyrighted Wikipedia article "Etalocib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
